To date, only three HDAC inhibitors have been approved by the FDA for the treatments of CTCL (vorinostat (SAHA) and romidepsin (Istodax)) and PTCL (belinostat (Beleodaq) and romidepsin). The gene discussed is HDAC9; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.